somewordstoolate/Q2CRBench-3 huggingface dataset:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA who have clinical parenchymal lung disease receive MTX or alternative DMARD(s) for treatment of joint disease?
Population: Patients with RA and parenchymal lung disease
Intervention: MTX
Comparator: Alternative csDMARD mono or combination therapy
TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with CHF NYHA class III or IV with inadequate response to csDMARDs add a TNF Inhibitor or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with CHF class III or IV with inadequate response to csDMARDs
Intervention: Add TNF Inhibitor
Comparator: Add Abatacept
Add Rituximab
Add IL-6 Receptor Inhibitor
Add JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA who are at target on a TNF Inhibitor and who develop CHF continue the TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?
Population: Patients with RA who are at target on TNF Inhibitor and who develop CHF
Intervention: Continue TNF Inhibitor
Comparator: Switch to Abatacept
Switch to Rituximab
Switch to IL-6 Receptor Inhibitor
Switch to JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with an inadequate response to csDMARDs, who have had non-melanoma skin cancer, receive a TNF Inhibitor or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, who have had non-melanoma skin cancer
Intervention: TNF Inhibitor
Comparator: Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs, who have had melanoma, receive a TNF Inhibitor or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, who have had melanoma
Intervention: TNF Inhibitor
Comparator: Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with DMARD-naïve RA with a previously treated lymphoproliferative disorder, who have low disease activity, receive csDMARDs or RTX?
Population: Patients with DMARD-naïve RA with a previously treated lymphoproliferative disorder, who have low disease activity
Intervention: csDMARDs
Comparator: RTX
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with DMARD-naïve RA who have moderate to high disease activity and a previously treated lymphoproliferative disorder receive csDMARDs or RTX?
Population: Patients with DMARD-naïve RA with a previously treated lymphoproliferative disorder who have moderate to high disease activity
Intervention: csDMARDs
Comparator: RTX
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs and a previously treated lymphoproliferative disorder receive RTX or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs and a previously treated lymphoproliferative disorder
Intervention: RTX
Comparator: Abatacept
TNF Inhibitor
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs and a previously treated lymphoproliferative disorder, who are NOT eligible for RTX, receive a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs and a previously treated lymphoproliferative disorder, and who are NOT eligible for RTX
Intervention: JAK Inhibitor
Comparator: Abatacept
TNF Inhibitor
IL-6 Receptor Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARD monotherapy and a remote history (≥ 5 years) of solid organ cancer and no known residual disease receive triple therapy (MTX or LEF + SSZ + HCQ) or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to csDMARD monotherapy and a remote history of solid organ cancer
Intervention: Triple therapy (MTX or LEF + SSZ + HCQ)
Comparator: TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARD monotherapy with recently treated (< 5 years) solid organ cancer receive triple therapy (MTX or LEF + SSZ + HCQ) or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to csDMARD monotherapy and recently treated (< 5 years) solid organ cancer
Intervention: Triple therapy
Comparator: TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA in low disease activity or remission, who are on DMARD(s) and are being treated with a check-point Inhibitor for cancer, stop or continue DMARDs?
Population: Patients with RA in low disease activity or remission on DMARD(s), receiving a check-point Inhibitor for cancer
Intervention: Stop DMARDs
Comparator: Continue DMARDs
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with moderate to high disease activity, who are being treated with a check-point Inhibitor for cancer, receive GCs or DMARDs?
Population: Patients with RA with moderate to high disease activity receiving a check-point Inhibitor for cancer
Intervention: GCs
Comparator: csDMARDs
TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA and low or very low risk of reactivation of Hepatitis B, who are initiating RTX, undergo frequent monitoring or start prophylactic anti-viral therapy?
Population: Patients with RA and low or very low risk of reactivation of Hepatitis B, who are initiating RTX
Intervention: Frequent monitoring
Comparator: Prophylactic anti-viral therapy
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA and low or very low risk of reactivation of Hepatitis B, who are initiating boDMARD or tsDMARD other than RTX, undergo frequent monitoring or start prophylactic anti-viral therapy?
Population: Patients with RA and low or very low risk of reactivation of Hepatitis B, who are initiating boDMARD or tsDMARD other than RTX
Intervention: Frequent monitoring
Comparator: Prophylactic anti-viral therapy
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA and moderate to very high risk of reactivation of Hepatitis B, who are initiating boDMARD or tsDMARDs, undergo frequent monitoring or start prophylactic anti-viral therapy?
Population: Patients with RA and moderate to very high risk of reactivation of Hepatitis B, who are initiating boDMARD or tsDMARDs
Intervention: Frequent monitoring
Comparator: Prophylactic anti-viral therapy
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with DMARD-naïve RA and chronic untreated Hepatitis C receive MTX or alternative DMARDs?
Population: Patients with DMARD-naïve RA and chronic untreated Hepatitis C
Intervention: MTX
Comparator: Alternative csDMARD mono or combination therapy
TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with an inadequate response to csDMARDs, and who have chronic untreated Hepatitis C, receive a TNF Inhibitor or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, and who have chronic untreated Hepatitis
Intervention: TNF Inhibitor
Comparator: Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA and NAFLD or NASH receive MTX or alternative DMARDs?
Population: patients with DMARD-naïve RA and NAFLD or NASH
Intervention: MTX
Comparator: Alternative DMARDs
TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to MTX and/or LEF, who have moderate to high disease activity and a prior serious infection within 3 years, add HCQ and SSZ or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to MTX and/or LEF, moderate to high disease activity, and a prior serious infection within 3 years
Intervention: Add SSZ and HCQ
Comparator: Add TNF Inhibitor
Add Abatacept
Add Rituximab
Add IL-6 Receptor Inhibitor
Add JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs, who have moderate to high disease activity and a prior serious infection within 3 years, receive abatacept or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, moderate to high disease activity, and a prior serious infection within 3 years
Intervention: Abatacept
Comparator: TNF Inhibitor
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs, who have moderate to high disease activity and a prior serious infection within 3 years, receive low dose GCs (≤ 10mg per day) or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, moderate to high disease activity, and a prior serious infection within 3 years
Intervention: Low dose GCs (≤ 10mg/day)
Comparator: TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs, who have moderate to high disease activity and a prior serious infection within 3 years, on low dose GCs (≤ 10mg per day), receive GCs 11-20mg per day or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, moderate to high disease activity, a prior serious infection within 3 years, and on low dose GCs (≤10mg per day)
Intervention: GCs 11-20mg per day
Comparator: TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to MTX and/or LEF, who have moderate to high disease activity and are on treatment for MAC, add HCQ and SSZ or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to MTX and/or LEF, moderate to high disease activity, on treatment for MAC
Intervention: Add SSZ and HCQ
Comparator: TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs, who have moderate to high disease activity and are on treatment for MAC, receive a TNF Inhibitor or a boDMARD targeting a different molecule or a tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, moderate to high disease activity, on treatment for MAC
Intervention: TNF Inhibitor
Comparator: Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2021 ACR RA
Clinical question: Should patients with RA with inadequate response to csDMARDs, who have moderate to high disease activity and are on treatment for MAC, receive low dose GCs (≤ 10mg per day) or a boDMARD or tsDMARD?
Population: Patients with RA with inadequate response to csDMARDs, moderate to high disease activity, on treatment for MAC
Intervention: GCs ≤ 10mg per day
Comparator: TNF Inhibitor
Abatacept
Rituximab
IL-6 Receptor Inhibitor
JAK Inhibitor
Outcomes:
Guideline: 2024 KDIGO CKD
Aspect: Evaluation of CKD
Clinical question: What is the diagnostic and prognostic benefit and safety of kidney biopsy among people with CKD?
Population: Adults and/or children with suspected or diagnosed CKD
Intervention: Native kidney biopsy
Comparator: Clinical or standard diagnosis or prognosis for studies evaluating diagnostic or prognostic benefit; No comparator for studies evaluating safety
Outcomes:
Clinical or standard diagnosis or prognosis for studies evaluating diagnostic or prognostic benefit; No comparator for studies evaluating safety: Mortality
Perirenal hematoma
Retroperitoneal hemorrhage
Guideline: 2024 KDIGO CKD
Aspect: Evaluation of CKD
Clinical question: What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?
Population: Adults and/or children with or without CKD
Intervention: Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)
Comparator: Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)
Outcomes:
Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker): Measurement bias (eGFR - mGFR) for cystatin C-based equations
Measurement bias (eGFR - mGFR) for creatinine + cystatin-based equations
Measurement bias (eGFR - mGFR) for creatinine-based equations
P30 for cystatin C-based equations
P30 for creatinine + cystatin C-based equations
P30 for creatinine-based equations
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What is the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) compared with placebo, usual care, or an active comparator among people with CKD in terms of mortality, progression of CKD, complications of CKD, and adverse events?
Population: Adults and/or children with CKD; subgroup of people (1) with type 2 diabetes (T2D), (2) without T2D, (3) with heart failure, and (4) without albuminuria
Intervention: SGLT2i (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin, sotagliflozin, tofogliflozin)
Comparator: Active comparator (e.g., another glucose-lowering agent), placebo, or usual care
Outcomes:
Active comparator (e.g., another glucose-lowering agent), placebo, or usual care: Kidney failure
All-cause hospitalizations
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?
Population: Adults and/or children with CKD and asymptomatic hyperuricemia
Intervention: Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad)
Comparator: Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care
Outcomes:
Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care: Progression of CKD to kidney failure (follow-up: range 3 months to 12 months)
Cutaneous reactions and hypersensitivity (follow-up: mean 3 months)
Hepatotoxicity (follow-up: range 3 months to 12 months)
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?
Population: Adults and/or children with CKD and hyperuricemia with subgroups for symptomatic and asymptomatic hyperuricemia
Intervention: Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, opiroxostat, rasburicase, sulfinpyrazone, lesinurad)
Comparator: Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care
Outcomes:
Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care: Progression of CKD to kidney failure (follow-up: range 12 months to 84 months)
Cutaneous reactions and hypersensitivity (follow-up: range 3 months to 41 months)
Hepatotoxicity (follow-up: range 3 months to 25 months)
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?
Population: Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)
Intervention: Aspirin
Comparator: Placebo
Outcomes:
Placebo: Cardiovascular mortality (follow-up: range 3.8 years to 5.4 years)
Composite cardiovascular events (follow-up: range 3.8 years to 5.4 years)
Myocardial infarction (follow-up: range 3.8 years to 5.4 years)
Stroke (follow-up: range 3.8 years to 5.4 years)
Major bleeding (follow-up: range 3.8 years to 5.4 years)
Minor bleeding (follow-up: range 3.8 years to 5.4 years)
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What are the effects of angiography or coronary revascularization compared with medical treatment among people with CKD and ischemic heart disease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)?
Population: Adults and/or children with CKD and ischemic heart disease
Intervention: Angiography or coronary revascularization
Comparator: Medical treatment
Outcomes:
Medical treatment: All-cause mortality  (follow-up: range 2 years to 10 years)
Cardiovascular mortality (follow-up: range 4.6 years to 5.6 years)
Composite cardiovascular events (follow-up: range 2 years to 10 years) 
Myocardial infarction (follow-up: range 2 years to 10 years)
Heart failure (follow-up: range 3 years to 5.6 years)
Acute kidney injury (follow-up: range 3 years to 5.6 years)
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?
Population: Adults and/or children with CKD and atrial fibrillation
Intervention: NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone
Comparator: Warfarin, placebo
Outcomes:
Warfarin, placebo: Any stroke (follow-up: range 1.9 years to 2.8 years)
Ischemic stroke (follow-up: range 1.8 years to 2.8 years)
Hemorrhagic stroke (follow-up: range 1.9 years to 2.8 years)
Guideline: 2024 KDIGO CKD
Aspect: Delaying CKD progression and managing its complications
Clinical question: What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?
Population: Adults and/or children with CKD and atrial fibrillation
Intervention: NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone
Comparator: Warfarin, placebo
Outcomes:
Warfarin, placebo: Intracranial hemorrhage (follow-up: range 1.9 years to 2.8 years)
Major bleeding (factor Xa inhibitors) (follow-up: range 6 months to 2.8 years)
Major bleeding (factor IIa inhibitors) (follow-up: median 1.8 years)
Clinically-relevant non-major bleeding (follow-up: range 1.9 years to 2.5 years)